Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 7/20 | 0.54 |
| ▸ | WNT3A | P56704 | 7/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409208 | 0.81 | ROCK2 (0.58) | CTNNB1WNT3ACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL31580716 | 0.80 | CTNNB1 (0.53) | CTNNB1WNT3ACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL4404815 | 0.78 | CTNNB1 (0.69) | CTNNB1WNT3ACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL18154915 | 0.76 | CTNNB1 (0.51) | CTNNB1WNT3ACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL3637193 | 0.76 | CTNNB1 (0.52) | CTNNB1WNT3AROCK2ROCK1MEN1 | |
| SCHEMBL29521387 | 0.76 | ROCK2 (0.64) | CTNNB1WNT3AROCK2ROCK1MEN1 | |
| SCHEMBL122504 | 0.76 | ROCK2 (0.64) | CTNNB1WNT3AROCK2ROCK1MEN1 | |
| SCHEMBL5404361 | 0.75 | MAOB (0.59) | CTNNB1WNT3ACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL145658 | 0.74 | CTNNB1 (0.60) | CTNNB1WNT3ACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL19086030 | 0.74 | MAOB (0.62) | CTNNB1WNT3AROCK2ROCK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | CTNNB1 2647/4885WNT3A 3494/4885CYP2D6 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.